Extended Data Fig. 5: Downstream pathway analysis following dosing of anti-muPD-1-muGITR-L bispecific in CT26 tumor syngeneic model, and rat/mouse cross reactivity of anti-huPD-1-huGITR-L bispecific. | Nature Cancer

Extended Data Fig. 5: Downstream pathway analysis following dosing of anti-muPD-1-muGITR-L bispecific in CT26 tumor syngeneic model, and rat/mouse cross reactivity of anti-huPD-1-huGITR-L bispecific.

From: An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy

Extended Data Fig. 5: Downstream pathway analysis following dosing of anti-muPD-1-muGITR-L bispecific in CT26 tumor syngeneic model, and rat/mouse cross reactivity of anti-huPD-1-huGITR-L bispecific.

(A) Gene ontology biological processes (GO-BP) enrichment analysis of intratumoral CD8+ T and NK cells between isotype and anti-PD-1-GITR-L-treated mice shows enriched pathways (hypergeometric test, adjusted P-values obtained by Benjamini-Hochberg procedure). (B to E) Binding of Alexa fluor (AF) 647-labeled anti-huPD-1-huGITR-L to anti-CD3 activated rat (B and C) and mouse splenocytes (D and E) (t = 48 and 72 hrs). Two independent experiments were performed.

Source data

Back to article page